Subscribe to Newsletter

How to Improve the Capturing of Antibody Fragments


Since 1986 and the first approval of therapeutic monoclonal antibody (mAb), the biopharmaceutical industry discovered a broad spectrum of diagnostic and therapeutic applications using antibody engineering. Some of the latest promising developments rely on antibody fragments. Antibody fragments are either separate functional subunits of antibodies or recombinant molecules, which, just like antibodies, are composed of immunoglobulin domains. The most popular fragments are Fab (Fragment antigen binding), scFv (single-chain Fragment variable), diabodies, and nanobodies[1].

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine